The estimated Net Worth of Mark L. Jacobson is at least $5.44 Milion dollars as of 9 August 2024. Mr Jacobson owns over 47,739 units of Axsome Therapeutics Inc stock worth over $4,872,108 and over the last 5 years he sold AXSM stock worth over $0. In addition, he makes $570,000 as COO & Sec. at Axsome Therapeutics Inc.
Mr has made over 3 trades of the Axsome Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 47,739 units of AXSM stock worth $192,866 on 9 August 2024.
The largest trade he's ever made was exercising 47,739 units of Axsome Therapeutics Inc stock on 9 August 2024 worth over $192,866. On average, Mr trades about 9,566 units every 14 days since 2020. As of 9 August 2024 he still owns at least 53,522 units of Axsome Therapeutics Inc stock.
You can see the complete history of Mr Jacobson stock trades at the bottom of the page.
Mark L. Jacobson is the COO & Sec. at Axsome Therapeutics Inc.
As the COO & Sec. of Axsome Therapeutics Inc, the total compensation of Mr Jacobson at Axsome Therapeutics Inc is $570,000. There are 4 executives at Axsome Therapeutics Inc getting paid more, with Herriot Tabuteau having the highest compensation of $4,715,750.
Mr Jacobson is 38, he's been the COO & Sec. of Axsome Therapeutics Inc since . There are 10 older and 3 younger executives at Axsome Therapeutics Inc. The oldest executive at Axsome Therapeutics Inc is David Marek, 55, who is the Chief Commercial Officer.
Mark's mailing address filed with the SEC is C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY, 10007.
Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony a Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
Axsome Therapeutics Inc executives and other stock owners filed with the SEC include: